Nicole Borau, MD
Endocrinology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Borau’s office at (408) 866-4070 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A107439 · Current
Licensed to practise in California · since 2009 · expires 2028-08-31 · Albany Medical College of Union University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$59,206
Medicare paid this office $59,206 for 222 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 135 | $24,658 | $107 |
| Injection, denosumab, 1 mg | 11 | $18,152 | None |
| Short return visit (20+ min) | 63 | $5,537 | $79 |
| New patient visit (45+ min) | 19 | $2,917 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 107 | $2,316 | $15 |
See all 9 services
| Return visit (30+ min) | 135 | $24,658 | $107 |
| Injection, denosumab, 1 mg | 11 | $18,152 | None |
| Short return visit (20+ min) | 63 | $5,537 | $79 |
| New patient visit (45+ min) | 19 | $2,917 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 107 | $2,316 | $15 |
| New patient visit (30+ min) | 16 | $1,258 | $79 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $471 | $25 |
| Injection of drug or substance under skin or into muscle | 11 | $161 | $11 |
| Hemoglobin a1c level | 16 | $152 | $10 |
Who their Medicare patients are
222 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 9% · Women 69% · Also on Medicaid 13% · Health risk score 1.23. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 55% · Chronic kidney disease 30% · Coronary heart disease 28% · Cancer 16% · Depression 16% · Atrial fibrillation 14% · Heart failure 12% · COPD 12% · Stroke 8%.
The office billed $237,187, Medicare allowed $81,511 and paid $59,206; for 1,668 services of 15 kinds; $20,260 of it was for drugs given in the office and $38,946 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 222 | 1,668 | 74 | 1.23 | $237,187 | $59,206 |
| 2023 | 215 | 4,139 | 73 | 1.22 | $283,095 | $68,822 |
| 2022 | 202 | 1,330 | 73 | 1.19 | $179,231 | $44,176 |
| 2021 | 176 | 1,235 | 73 | 1.29 | $123,052 | $34,895 |
| 2020 | 148 | 460 | 74 | 1.33 | $67,401 | $22,057 |
| 2019 | 42 | 46 | 74 | 1.21 | $16,452 | $3,115 |
| 2018 | 124 | 254 | 73 | 1.29 | $85,946 | $19,345 |
| 2017 | 110 | 251 | 73 | 1.60 | $73,069 | $18,903 |
| 2016 | 101 | 238 | 71 | 1.56 | $68,257 | $17,856 |
| 2015 | 109 | 480 | 72 | 1.43 | $86,400 | $24,170 |
| 2014 | 87 | 253 | 71 | 1.47 | $62,542 | $17,512 |
| 2013 | 32 | 73 | 70 | 1.46 | $18,309 | $6,658 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 141 | $27,349 | $106 |
| Injection, denosumab, 1 mg | 11 | $17,864 | None |
| Short return visit (20+ min) | 65 | $5,977 | $75 |
| New patient visit (45+ min) | 22 | $3,253 | $148 |
| New patient visit (30+ min) | 21 | $1,799 | $86 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $860 | $24 |
| Injection of drug or substance under skin or into muscle | 13 | $387 | $12 |
2022: 6 services
| Return visit (30+ min) | 124 | $26,130 | $113 |
| Short return visit (20+ min) | 58 | $5,362 | $79 |
| New patient visit (45+ min) | 24 | $3,567 | $149 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $1,721 | $57 |
| New patient visit (30+ min) | 14 | $1,244 | $89 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $1,078 | $22 |
2021: 7 services
| Return visit (30+ min) | 88 | $15,946 | $117 |
| Short return visit (20+ min) | 70 | $5,853 | $71 |
| Telephone medical discussion with physician, 11-20 minutes | 39 | $4,332 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $2,653 | $115 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $1,187 | $22 |
| New patient visit (30+ min) | 12 | $1,139 | $95 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $280 | $22 |
2020: 6 services
| Return visit (30+ min) | 50 | $6,212 | $90 |
| Telephone medical discussion with physician, 11-20 minutes | 60 | $5,524 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $2,101 | $96 |
| Short return visit (20+ min) | 33 | $2,036 | $57 |
| Telephone medical discussion with physician, 5-10 minutes | 52 | $1,982 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $873 | $20 |
2019: 1 service
| Return visit (30+ min) | 28 | $2,106 | $75 |
2018: 4 services
| Return visit (30+ min) | 79 | $12,599 | $86 |
| Short return visit (20+ min) | 39 | $2,411 | $56 |
| New patient visit (30+ min) | 13 | $1,095 | $84 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $359 | $17 |
2017: 4 services
| Return visit (30+ min) | 75 | $11,189 | $85 |
| New patient visit (45+ min) | 19 | $2,579 | $136 |
| Short return visit (20+ min) | 27 | $1,913 | $58 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $604 | $18 |
2016: 5 services
| Return visit (30+ min) | 59 | $8,996 | $90 |
| Short return visit (20+ min) | 34 | $2,662 | $59 |
| New patient visit (45+ min) | 17 | $2,407 | $142 |
| New patient visit (30+ min) | 11 | $954 | $87 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $509 | $16 |
2015: 7 services
| Return visit (30+ min) | 66 | $11,770 | $97 |
| New patient visit (45+ min) | 28 | $4,051 | $145 |
| Fine needle aspiration using imaging guidance | 14 | $2,622 | $146 |
| Short return visit (20+ min) | 21 | $1,604 | $70 |
| New patient visit (30+ min) | 12 | $1,152 | $96 |
| Ultrasonic guidance for needle placement | 14 | $854 | $61 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $644 | $20 |
2014: 5 services
| Return visit (30+ min) | 48 | $7,563 | $87 |
| New patient visit (45+ min) | 15 | $1,893 | $126 |
| New patient visit (30+ min) | 19 | $1,890 | $99 |
| Short return visit (20+ min) | 24 | $1,654 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $947 | $18 |
2013: 2 services
| Return visit (30+ min) | 18 | $2,684 | $99 |
| New patient visit (45+ min) | 17 | $2,436 | $143 |
Drugs they prescribed that Part D paid
$1,204,329
Pharmacies billed $1,204,329 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,556) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,370 generic and 1,042 brand-name prescriptions · $1,204,329 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 142 | $296,721 | $2,090 |
| Jardiance | 155 | $237,314 | $1,531 |
| Trulicity | 51 | $106,743 | $2,093 |
| Tradjenta | 35 | $50,144 | $1,433 |
| Farxiga | 30 | $45,221 | $1,507 |
See all 45 drugs
| Ozempic | 142 | $296,721 | $2,090 |
| Jardiance | 155 | $237,314 | $1,531 |
| Trulicity | 51 | $106,743 | $2,093 |
| Tradjenta | 35 | $50,144 | $1,433 |
| Farxiga | 30 | $45,221 | $1,507 |
| Toujeo Max Solostar | 29 | $44,752 | $1,543 |
| Humalog Kwikpen U-200 | 17 | $43,978 | $2,587 |
| Mounjaro | 25 | $38,968 | $1,559 |
| Rybelsus | 15 | $38,595 | $2,573 |
| Januvia | 20 | $29,815 | $1,491 |
| Prolia | 15 | $24,898 | $1,660 |
| Toujeo Solostar | 18 | $24,059 | $1,337 |
| Tresiba Flextouch U-200 | 13 | $12,696 | $977 |
| Basaglar Kwikpen U-100 | 18 | $8,704 | $484 |
| Humalog Kwikpen U-100 | 37 | $8,540 | $231 |
| Nano 2nd Gen Pen Needle | 75 | $7,857 | $105 |
| Tresiba Flextouch U-100 | 31 | $7,701 | $248 |
| Lantus Solostar | 63 | $7,261 | $115 |
| Novolog Flexpen | 18 | $5,515 | $306 |
| Levothyroxine | 351 | $5,292 | $15 |
| Synthroid | 54 | $5,048 | $93 |
| Metformin | 207 | $2,479 | $12 |
| Humalog | 11 | $1,929 | $175 |
| Tirosint | 11 | $1,778 | $162 |
| Atorvastatin | 94 | $1,480 | $16 |
| Ezetimibe | 43 | $1,392 | $32 |
| Ultra-Fine Short Pen Needle | 17 | $1,325 | $78 |
| Metformin Hcl Er | 70 | $1,209 | $17 |
| Pravastatin | 59 | $1,110 | $19 |
| Rosuvastatin | 52 | $1,068 | $21 |
| Repaglinide | 35 | $1,006 | $29 |
| Ultra-Fine Mini Pen Needle | 11 | $905 | $82 |
| Glipizide | 70 | $746 | $11 |
| Methimazole | 68 | $677 | $10 |
| Hydrocortisone | 11 | $625 | $57 |
| Alendronate | 58 | $559 | $10 |
| Lisinopril | 55 | $521 | $9 |
| Losartan | 56 | $499 | $9 |
| Liothyronine | 13 | $451 | $35 |
| Glipizide Er | 21 | $435 | $21 |
| Glimepiride | 37 | $355 | $10 |
| Simvastatin | 22 | $331 | $15 |
| Cabergoline | 14 | $268 | $19 |
| Amlodipine Besylate | 23 | $238 | $10 |
| Pioglitazone | 11 | $200 | $18 |
Year by year
| 2024 | 2,556 | 377 | 0% (0) | 41% | $1,204,329 |
| 2023 | 2,785 | 370 | 0% (0) | 43% | $1,549,542 |
| 2022 | 2,372 | 317 | 0% (0) | 42% | $1,121,178 |
| 2021 | 2,034 | 257 | 0% (0) | 48% | $1,002,449 |
| 2020 | 1,659 | 234 | 0% (0) | 46% | $644,917 |
| 2019 | 1,118 | 190 | 0% (0) | 45% | $350,342 |
| 2018 | 1,001 | 131 | None | 35% | $217,615 |
| 2017 | 1,005 | 124 | 0% (0) | 37% | $183,025 |
| 2016 | 863 | 112 | 0% (0) | 34% | $135,215 |
| 2015 | 604 | 91 | 0% (0) | 40% | $114,247 |
| 2014 | 369 | 59 | 0% (0) | 42% | $63,371 |
| 2013 | 104 | 23 | 0% (0) | 32% | $19,082 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Jardiance | 165 | $276,916 | $1,678 |
| Ozempic | 131 | $261,695 | $1,998 |
| Trulicity | 80 | $183,185 | $2,290 |
| Farxiga | 44 | $60,618 | $1,378 |
| Tradjenta | 37 | $60,400 | $1,632 |
| Lantus Solostar | 96 | $58,556 | $610 |
| Toujeo Max Solostar | 45 | $48,837 | $1,085 |
| Rybelsus | 16 | $48,690 | $3,043 |
| Humalog Kwikpen U-200 | 15 | $43,811 | $2,921 |
| Novolog Flexpen | 29 | $35,656 | $1,230 |
| Humulin 70/30 Kwikpen | 15 | $33,499 | $2,233 |
| Humalog Kwikpen U-100 | 26 | $32,412 | $1,247 |
| Toujeo Solostar | 18 | $31,037 | $1,724 |
| Prolia | 18 | $30,011 | $1,667 |
| Januvia | 13 | $21,106 | $1,624 |
| Mounjaro | 14 | $20,166 | $1,440 |
| Tresiba Flextouch U-200 | 15 | $18,808 | $1,254 |
| Tresiba Flextouch U-100 | 23 | $11,847 | $515 |
| Vascepa | 21 | $9,903 | $472 |
| Basaglar Kwikpen U-100 | 18 | $8,582 | $477 |
| Nano 2nd Gen Pen Needle | 80 | $8,173 | $102 |
| Synthroid | 78 | $7,992 | $102 |
| Levothyroxine | 389 | $6,769 | $17 |
| Icosapent Ethyl | 17 | $6,676 | $393 |
| Levemir Flexpen | 11 | $5,535 | $503 |
| Humulin 70-30 | 12 | $4,565 | $380 |
| Insulin Lispro Kwikpen U-100 | 16 | $3,803 | $238 |
| Ultra-Fine Mini Pen Needle | 23 | $2,667 | $116 |
| Repaglinide | 26 | $2,471 | $95 |
| Atorvastatin | 121 | $2,170 | $18 |
| Metformin | 170 | $1,919 | $11 |
| Ultra-Fine Short Pen Needle | 12 | $1,904 | $159 |
| Ezetimibe | 33 | $1,875 | $57 |
| Metformin Hcl Er | 77 | $1,733 | $23 |
| Rosuvastatin | 67 | $1,329 | $20 |
| Glipizide | 87 | $1,278 | $15 |
| Methimazole | 81 | $1,182 | $15 |
| Pravastatin | 64 | $1,005 | $16 |
| Ultra-Fine Nano Pen Needle | 14 | $906 | $65 |
| Losartan | 52 | $795 | $15 |
| Glimepiride | 36 | $690 | $19 |
| Simvastatin | 35 | $599 | $17 |
| Amlodipine Besylate | 33 | $546 | $17 |
| Alendronate | 33 | $500 | $15 |
| Pioglitazone | 11 | $458 | $42 |
| Glipizide Er | 22 | $451 | $21 |
| Lisinopril | 59 | $369 | $6 |
| Irbesartan | 11 | $328 | $30 |
| Fenofibrate | 20 | $295 | $15 |
2022: 43 drugs
| Trulicity | 97 | $169,151 | $1,744 |
| Jardiance | 102 | $164,424 | $1,612 |
| Ozempic | 49 | $95,595 | $1,951 |
| Farxiga | 72 | $81,081 | $1,126 |
| Rybelsus | 24 | $61,250 | $2,552 |
| Lantus Solostar | 81 | $46,187 | $570 |
| Tradjenta | 28 | $42,983 | $1,535 |
| Toujeo Max Solostar | 36 | $42,776 | $1,188 |
| Humalog Kwikpen U-200 | 12 | $35,711 | $2,976 |
| Toujeo Solostar | 17 | $34,162 | $2,010 |
| Humalog Kwikpen U-100 | 19 | $23,966 | $1,261 |
| Novolog Flexpen | 28 | $22,863 | $817 |
| Lantus | 12 | $21,291 | $1,774 |
| Prolia | 14 | $21,216 | $1,515 |
| Januvia | 14 | $17,915 | $1,280 |
| Vascepa | 33 | $17,384 | $527 |
| Basaglar Kwikpen U-100 | 21 | $9,206 | $438 |
| Humulin N Kwikpen | 13 | $7,598 | $584 |
| Levothyroxine | 333 | $7,381 | $22 |
| Tresiba Flextouch U-100 | 13 | $7,308 | $562 |
| Nano 2nd Gen Pen Needle | 75 | $6,953 | $93 |
| Synthroid | 60 | $6,211 | $104 |
| Insulin Lispro Kwikpen U-100 | 23 | $4,271 | $186 |
| Ultra-Fine Short Pen Needle | 12 | $2,489 | $207 |
| Atorvastatin | 129 | $2,371 | $18 |
| Ultra-Fine Mini Pen Needle | 18 | $1,892 | $105 |
| Repaglinide | 26 | $1,880 | $72 |
| Metformin | 144 | $1,675 | $12 |
| Fenofibrate | 30 | $1,400 | $47 |
| Ezetimibe | 15 | $1,330 | $89 |
| Metformin Hcl Er | 49 | $1,195 | $24 |
| Pravastatin | 68 | $1,119 | $16 |
| Rosuvastatin | 45 | $1,023 | $23 |
| Glimepiride | 30 | $822 | $27 |
| Methimazole | 63 | $704 | $11 |
| Glipizide | 52 | $696 | $13 |
| Losartan | 47 | $679 | $14 |
| Ultra-Fine Nano Pen Needle | 13 | $616 | $47 |
| Alendronate | 45 | $521 | $12 |
| Glipizide Er | 20 | $481 | $24 |
| Simvastatin | 33 | $434 | $13 |
| Lisinopril | 53 | $426 | $8 |
| Amlodipine Besylate | 23 | $369 | $16 |
2021: 40 drugs
| Trulicity | 110 | $154,415 | $1,404 |
| Jardiance | 91 | $134,013 | $1,473 |
| Rybelsus | 45 | $69,391 | $1,542 |
| Lantus Solostar | 93 | $54,252 | $583 |
| Humalog Kwikpen U-200 | 29 | $47,798 | $1,648 |
| Toujeo Solostar | 34 | $46,007 | $1,353 |
| Tradjenta | 29 | $39,772 | $1,371 |
| Farxiga | 36 | $35,740 | $993 |
| Lantus | 22 | $33,438 | $1,520 |
| Januvia | 23 | $29,116 | $1,266 |
| Humalog Kwikpen U-100 | 33 | $28,332 | $859 |
| Ozempic | 14 | $27,294 | $1,950 |
| Toujeo Max Solostar | 18 | $25,960 | $1,442 |
| Novolog Flexpen | 19 | $23,639 | $1,244 |
| Humalog | 13 | $23,456 | $1,804 |
| Humulin 70/30 Kwikpen | 15 | $23,265 | $1,551 |
| Levemir Flextouch | 12 | $21,455 | $1,788 |
| Vascepa | 41 | $19,650 | $479 |
| Basaglar Kwikpen U-100 | 19 | $14,342 | $755 |
| Insulin Lispro | 15 | $10,276 | $685 |
| Levothyroxine | 297 | $7,620 | $26 |
| Nano 2nd Gen Pen Needle | 71 | $6,471 | $91 |
| Synthroid | 47 | $5,691 | $121 |
| Insulin Lispro Kwikpen U-100 | 18 | $5,537 | $308 |
| Ultra-Fine Nano Pen Needle | 23 | $2,452 | $107 |
| Ultra-Fine Mini Pen Needle | 20 | $1,943 | $97 |
| Metformin | 107 | $1,209 | $11 |
| Atorvastatin | 73 | $1,177 | $16 |
| Fenofibrate | 31 | $1,141 | $37 |
| Metformin Hcl Er | 48 | $805 | $17 |
| Rosuvastatin | 34 | $757 | $22 |
| Methimazole | 58 | $744 | $13 |
| Glipizide | 75 | $710 | $9 |
| Alendronate | 48 | $639 | $13 |
| Pravastatin | 27 | $469 | $17 |
| Glimepiride | 17 | $370 | $22 |
| Simvastatin | 23 | $319 | $14 |
| Losartan | 18 | $317 | $18 |
| Amlodipine Besylate | 19 | $220 | $12 |
| Lisinopril | 38 | $212 | $6 |
2020: 36 drugs
| Jardiance | 60 | $71,349 | $1,189 |
| Lantus Solostar | 103 | $54,050 | $525 |
| Trulicity | 31 | $47,953 | $1,547 |
| Humalog Kwikpen U-200 | 23 | $42,867 | $1,864 |
| Toujeo Solostar | 32 | $41,754 | $1,305 |
| Tradjenta | 39 | $39,191 | $1,005 |
| Januvia | 24 | $32,330 | $1,347 |
| Levemir Flextouch | 17 | $28,732 | $1,690 |
| Lantus | 18 | $26,333 | $1,463 |
| Novolog Flexpen | 21 | $20,855 | $993 |
| Basaglar Kwikpen U-100 | 25 | $20,498 | $820 |
| Humalog Kwikpen U-100 | 25 | $19,505 | $780 |
| Humalog | 15 | $16,340 | $1,089 |
| Baqsimi | 25 | $14,851 | $594 |
| Insulin Lispro | 13 | $7,626 | $587 |
| Levothyroxine | 269 | $7,257 | $27 |
| Ultra-Fine Nano Pen Needle | 67 | $5,819 | $87 |
| Synthroid | 50 | $4,787 | $96 |
| Insulin Lispro Kwikpen U-100 | 15 | $4,245 | $283 |
| Ultra-Fine Mini Pen Needle | 17 | $1,588 | $93 |
| Nano 2nd Gen Pen Needle | 16 | $1,414 | $88 |
| Metformin | 100 | $977 | $10 |
| Atorvastatin | 44 | $866 | $20 |
| Methimazole | 61 | $832 | $14 |
| Glimepiride | 28 | $825 | $29 |
| Glipizide | 75 | $798 | $11 |
| Hydrocortisone | 12 | $761 | $63 |
| Alendronate | 43 | $564 | $13 |
| Metformin Hcl Er | 31 | $509 | $16 |
| Fenofibrate | 12 | $431 | $36 |
| Pravastatin | 23 | $403 | $18 |
| Gabapentin | 11 | $237 | $22 |
| Losartan | 17 | $178 | $10 |
| Amlodipine Besylate | 16 | $138 | $9 |
| Simvastatin | 18 | $123 | $7 |
| Lisinopril | 28 | $121 | $4 |
2019: 26 drugs
| Jardiance | 36 | $37,035 | $1,029 |
| Toujeo Solostar | 29 | $34,158 | $1,178 |
| Lantus Solostar | 61 | $24,099 | $395 |
| Humalog Kwikpen U-200 | 15 | $23,149 | $1,543 |
| Januvia | 20 | $22,897 | $1,145 |
| Humalog Kwikpen U-100 | 24 | $20,209 | $842 |
| Tradjenta | 23 | $19,899 | $865 |
| Novolog Flexpen | 16 | $16,757 | $1,047 |
| Levemir Flextouch | 16 | $16,746 | $1,047 |
| Basaglar Kwikpen U-100 | 22 | $15,533 | $706 |
| Novolog Mix 70-30 Flexpen | 12 | $13,838 | $1,153 |
| Levothyroxine | 194 | $4,780 | $25 |
| Ultra-Fine Nano Pen Needle | 52 | $4,228 | $81 |
| Synthroid | 41 | $2,852 | $70 |
| Repaglinide | 18 | $1,824 | $101 |
| Ultra-Fine Mini Pen Needle | 11 | $1,228 | $112 |
| Methimazole | 72 | $949 | $13 |
| Alendronate | 71 | $832 | $12 |
| Glimepiride | 28 | $823 | $29 |
| Metformin | 52 | $612 | $12 |
| Atorvastatin | 23 | $539 | $23 |
| Glipizide | 30 | $411 | $14 |
| Losartan | 18 | $227 | $13 |
| Amlodipine Besylate | 15 | $172 | $11 |
| Simvastatin | 11 | $172 | $16 |
| Lisinopril | 13 | $107 | $8 |
2018: 19 drugs
| Lantus Solostar | 34 | $35,824 | $1,054 |
| Toujeo Solostar | 16 | $31,328 | $1,958 |
| Januvia | 21 | $17,478 | $832 |
| Humalog Kwikpen U-100 | 14 | $12,536 | $895 |
| Novolog Flexpen | 12 | $8,296 | $691 |
| Levothyroxine | 233 | $3,938 | $17 |
| Repaglinide | 12 | $1,836 | $153 |
| Synthroid | 41 | $1,736 | $42 |
| Ultra-Fine Nano Pen Needle | 20 | $1,523 | $76 |
| Methimazole | 84 | $1,007 | $12 |
| Hydrocortisone | 13 | $739 | $57 |
| Glipizide | 59 | $565 | $10 |
| Alendronate | 83 | $554 | $7 |
| Metformin | 45 | $486 | $11 |
| Glimepiride | 23 | $412 | $18 |
| Atorvastatin | 15 | $344 | $23 |
| Losartan | 35 | $206 | $6 |
| Lisinopril | 28 | $146 | $5 |
| Gemfibrozil | 13 | $130 | $10 |
2017: 19 drugs
| Toujeo Solostar | 24 | $31,183 | $1,299 |
| Lantus Solostar | 35 | $23,350 | $667 |
| Januvia | 28 | $16,775 | $599 |
| Humalog Kwikpen U-100 | 18 | $16,417 | $912 |
| Levothyroxine | 291 | $4,673 | $16 |
| Synthroid | 49 | $1,784 | $36 |
| Ultra-Fine Nano Pen Needle | 19 | $1,329 | $70 |
| Hydrocortisone | 14 | $633 | $45 |
| Methimazole | 65 | $558 | $9 |
| Alendronate | 80 | $523 | $7 |
| Glipizide | 59 | $417 | $7 |
| Metformin | 41 | $369 | $9 |
| Glimepiride | 23 | $300 | $13 |
| Losartan | 22 | $98 | $4 |
| Gemfibrozil | 12 | $96 | $8 |
| Hydrochlorothiazide | 16 | $75 | $5 |
| Amlodipine Besylate | 11 | $75 | $7 |
| Lisinopril | 12 | $40 | $3 |
| Metoprolol | 11 | $18 | $2 |
2016: 18 drugs
| Toujeo Solostar | 18 | $18,247 | $1,014 |
| Humalog Kwikpen U-100 | 24 | $18,198 | $758 |
| Lantus Solostar | 27 | $17,310 | $641 |
| Januvia | 16 | $10,189 | $637 |
| Tradjenta | 12 | $5,064 | $422 |
| Levothyroxine | 260 | $3,782 | $15 |
| Bd Ultra-Fine Pen Needle | 23 | $1,521 | $66 |
| Alendronate | 87 | $837 | $10 |
| Hydrocortisone | 16 | $635 | $40 |
| Methimazole | 60 | $620 | $10 |
| Synthroid | 20 | $571 | $29 |
| Metformin | 29 | $520 | $18 |
| Glimepiride | 22 | $405 | $18 |
| Atorvastatin | 11 | $349 | $32 |
| Glipizide | 38 | $284 | $7 |
| Hydrochlorothiazide | 21 | $100 | $5 |
| Lisinopril | 20 | $43 | $2 |
| Metoprolol | 12 | $19 | $2 |
2015: 11 drugs
| Lantus Solostar | 33 | $30,514 | $925 |
| Humalog Kwikpen U-100 | 29 | $21,400 | $738 |
| Novolog Flexpen | 16 | $13,632 | $852 |
| Levothyroxine | 183 | $2,835 | $15 |
| Bd Ultra-Fine Pen Needle | 26 | $1,555 | $60 |
| Synthroid | 23 | $653 | $28 |
| Methimazole | 46 | $525 | $11 |
| Alendronate | 39 | $377 | $10 |
| Atorvastatin | 17 | $286 | $17 |
| Glipizide | 29 | $198 | $7 |
| Metformin | 23 | $182 | $8 |
2014: 9 drugs
| Lantus Solostar | 35 | $21,634 | $618 |
| Humalog | 15 | $9,660 | $644 |
| Novolog Flexpen | 11 | $4,342 | $395 |
| Bd Ultra-Fine Pen Needle | 28 | $1,412 | $50 |
| Levothyroxine | 89 | $1,232 | $14 |
| Synthroid | 22 | $719 | $33 |
| Methimazole | 41 | $673 | $16 |
| Alendronate | 18 | $213 | $12 |
| Metformin | 15 | $163 | $11 |
2013: 2 drugs
| Levothyroxine | 33 | $393 | $12 |
| Methimazole | 12 | $246 | $21 |
Money from drug and device companies
$49 in 2025
| 2025 | 2 | 2 | None | $49 |
| 2022 | 1 | 1 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Minimed 780g | $31 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $19 | 1 payment
|
See all 2 published payments
| Medtronic | Meals · 2025-10-06 | Minimed 780g | $31 |
| Abbott Laboratories | Meals · 2025-02-07 | Freestyle Libre 3 | $19 |
See earlier years (2022)
2022: $24
| Abbott Laboratories | Freestyle Libre 2 | $24 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285836403
- Licence
- CA A107439California A107439: Current · expires 2028-08-31
- Trained
- Albany Medical College of Union University, 2005
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 2585 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2007-06-01
- NPI last updated
- 2020-11-11
- NPI record certified
- 2020-11-11
This is when the NPI record was last certified, not a medical board exam.